foscarnet has been researched along with Genital Herpes in 35 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 9.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 9.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Sequential human-immunodeficiency virus type 1 (HIV-1) isolates from an acquired immunodeficiency syndrome (AIDS) patient on long-term foscarnet and zidovudine therapy were examined for the emergence of foscarnet resistance." | 7.69 | Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. ( Birch, C; Hoy, J; McGavin, K; Tachedjian, G, 1994) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 7.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "The activity of phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) against four strains of herpes simplex virus type 1 (HSV-1) and four strains of HSV-2 were compared in tissue culture and in a murine model of genital herpes." | 7.66 | A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. ( Glasgow, LA; Kern, ER; Overall, JC; Richards, JT, 1981) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with foscarnet cream was not associated with any significant side effects." | 6.66 | Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. ( Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 6.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "Genital herpes is an important cofactor for acquisition of human immunodeficiency virus (HIV) infection, and effective prophylaxis is a helpful strategy to halt both HIV and herpes simplex virus (HSV) transmission." | 5.48 | The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. ( Andrei, G; Gillemot, S; Snoeck, R; Topalis, D, 2018) |
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 5.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 5.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "Recurrent anogenital herpes simplex virus infections are common in patients with human immunodeficiency virus (HIV), of whom approximately 5% develop resistance to acyclovir." | 3.85 | Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV). ( Arinze, F; Raffanti, S; Shaver, A, 2017) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Sequential human-immunodeficiency virus type 1 (HIV-1) isolates from an acquired immunodeficiency syndrome (AIDS) patient on long-term foscarnet and zidovudine therapy were examined for the emergence of foscarnet resistance." | 3.69 | Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. ( Birch, C; Hoy, J; McGavin, K; Tachedjian, G, 1994) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 3.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "A rapid screening test for antiviral susceptibility to acyclovir and foscarnet was evaluated in 320 herpes simplex virus (HSV) isolates from 197 patients." | 3.69 | A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates. ( Elbeik, T; Mills, J; Safrin, S, 1994) |
| "In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks." | 3.68 | [Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS]. ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991) |
| "The activity of phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) against four strains of herpes simplex virus type 1 (HSV-1) and four strains of HSV-2 were compared in tissue culture and in a murine model of genital herpes." | 3.66 | A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. ( Glasgow, LA; Kern, ER; Overall, JC; Richards, JT, 1981) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with foscarnet cream was not associated with any significant side effects." | 2.66 | Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. ( Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 2.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | 2.36 | [Herpes simplex]. ( Fanta, D, 1981) |
| "Genital herpes is an important cofactor for acquisition of human immunodeficiency virus (HIV) infection, and effective prophylaxis is a helpful strategy to halt both HIV and herpes simplex virus (HSV) transmission." | 1.48 | The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. ( Andrei, G; Gillemot, S; Snoeck, R; Topalis, D, 2018) |
| "The foscarnet resistance was associated with an S725G mutation in a conserved region (region II) of the herpesvirus DNA pol gene." | 1.31 | Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient. ( Birch, C; Chibo, D; Doherty, R; Mijch, A, 2002) |
| " In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg." | 1.27 | Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. ( Hsiung, GD; Mayo, DR, 1984) |
| "Using a guinea pig model of genital herpes simplex virus (HSV) type 2 infection, phosphonoformate treatment initiated after the onset of symptoms had a therapeutic effect on the outcome of disease." | 1.27 | Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs. ( Hsiung, GD; Lucia, HL; Mayo, DR, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (28.57) | 18.7374 |
| 1990's | 14 (40.00) | 18.2507 |
| 2000's | 9 (25.71) | 29.6817 |
| 2010's | 2 (5.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arinze, F | 1 |
| Shaver, A | 1 |
| Raffanti, S | 1 |
| Andrei, G | 2 |
| Gillemot, S | 1 |
| Topalis, D | 1 |
| Snoeck, R | 2 |
| Yudin, MH | 1 |
| Kaul, R | 1 |
| Brown, TJ | 1 |
| McCrary, M | 1 |
| Tyring, SK | 1 |
| Chibo, D | 1 |
| Mijch, A | 1 |
| Doherty, R | 1 |
| Birch, C | 2 |
| Brummitt, CF | 1 |
| Ghislanzoni, M | 1 |
| Cusini, M | 1 |
| Zerboni, R | 1 |
| Alessi, E | 1 |
| Mayo, DR | 2 |
| Hsiung, GD | 2 |
| Kern, ER | 1 |
| Richards, JT | 1 |
| Overall, JC | 1 |
| Glasgow, LA | 1 |
| Fanta, D | 1 |
| Lucia, HL | 1 |
| Li, YY | 1 |
| Minagawa, H | 1 |
| Tanaka, S | 1 |
| Mori, R | 1 |
| Tachedjian, G | 1 |
| Hoy, J | 1 |
| McGavin, K | 1 |
| Gérard, M | 1 |
| Silverman, A | 1 |
| Hedderman, A | 1 |
| Balzarini, J | 1 |
| Sadzot-Delvaux, C | 1 |
| Tricot, G | 1 |
| Clumeck, N | 1 |
| De Clercq, E | 1 |
| Safrin, S | 3 |
| Elbeik, T | 1 |
| Mills, J | 2 |
| Kemmerly, S | 1 |
| Plotkin, B | 1 |
| Smith, T | 1 |
| Weissbach, N | 1 |
| De Veranez, D | 1 |
| Phan, LD | 1 |
| Cohn, D | 1 |
| Baumann, R | 1 |
| Wunderli, W | 2 |
| Riess, C | 1 |
| Vogt, M | 1 |
| Beasley, KL | 1 |
| Cooley, GE | 1 |
| Kao, GF | 1 |
| Lowitt, MH | 1 |
| Burnett, JW | 1 |
| Aurelian, L | 1 |
| Scoular, A | 1 |
| Barton, S | 1 |
| Pechère, M | 1 |
| Trellu-Toutous, L | 1 |
| Harms, M | 1 |
| Saura, JH | 1 |
| Krischer, J | 1 |
| Alvarez-McLeod, A | 1 |
| Havlik, J | 1 |
| Drew, KE | 1 |
| Bernstein, DI | 1 |
| Ireland, J | 1 |
| Bourne, N | 1 |
| Arnulf, B | 1 |
| Chebbi, F | 1 |
| Lefrere, F | 1 |
| Ait Arkoub, Z | 1 |
| Varet, B | 1 |
| Fillet, AM | 1 |
| Aoki, FY | 2 |
| Bestman-Smith, J | 1 |
| Boivin, G | 1 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Davis, R | 1 |
| Hafner, R | 1 |
| Rush, J | 1 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| Bratzke, B | 1 |
| Orfanos, CE | 1 |
| Stavermann, T | 1 |
| Ehlers, G | 1 |
| Spitzbart, H | 1 |
| Seyffert, C | 1 |
| Thust, U | 1 |
| Chatis, PA | 1 |
| Miller, CH | 1 |
| Schrager, LE | 1 |
| Crumpacker, CS | 1 |
| Youle, MM | 1 |
| Hawkins, DA | 1 |
| Collins, P | 1 |
| Shanson, DC | 1 |
| Evans, R | 1 |
| Oliver, N | 1 |
| Lawrence, A | 1 |
| Barton, SE | 1 |
| Munday, PE | 1 |
| Kinghorn, GR | 1 |
| van der Meijden, WI | 1 |
| Stolz, E | 1 |
| Notowicz, A | 1 |
| Rashid, S | 1 |
| Schuller, JL | 1 |
| Essex-Cater, AJ | 1 |
| Kuijpers, MH | 1 |
| Sacks, SL | 1 |
| Portnoy, J | 1 |
| Lawee, D | 1 |
| Schlech, W | 1 |
| Tyrrell, DL | 1 |
| Poisson, M | 1 |
| Bright, C | 1 |
| Kaluski, J | 1 |
| Lim, KB | 1 |
| Doraisingham, S | 1 |
| Thirumoorthy, T | 1 |
| Lee, CT | 1 |
| Ling, AE | 1 |
| Tan, T | 1 |
| Wallin, J | 1 |
| Lernestedt, JO | 1 |
| Ogenstad, S | 1 |
| Lycke, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for foscarnet and Genital Herpes
| Article | Year |
|---|---|
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
[Herpes simplex].
Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe | 1981 |
Management of genital herpes in HIV-infected patients.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral A | 2001 |
5 trials available for foscarnet and Genital Herpes
| Article | Year |
|---|---|
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
Topics: Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Female; Foscarnet; Herpes Ge | 1986 |
Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
Topics: Administration, Topical; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Double-Blind | 1987 |
Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Double | 1986 |
Topical treatment of recurrent genital herpes infections with foscarnet.
Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Erythema; Female; Fos | 1985 |
27 other studies available for foscarnet and Genital Herpes
| Article | Year |
|---|---|
Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Genitalis; Herpesvirus 2, Hum | 2017 |
The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Topics: Acyclovir; Amino Acid Substitution; Antiviral Agents; Cells, Cultured; DNA Mutational Analysis; DNA- | 2018 |
Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy.
Topics: Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Aminoquinolines; Antineoplast | 2008 |
Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA-Directed DNA Polymera | 2002 |
Imiquimod 5% cream for the treatment of recurrent, acyclovir-resistant genital herpes.
Topics: Acyclovir; Administration, Topical; Aged; Aminoquinolines; Antiviral Agents; Arthritis, Rheumatoid; | 2006 |
Chronic hypertrophic acyclovir-resistant genital herpes treated with topical cidofovir and with topical foscarnet at recurrence in an HIV-positive man.
Topics: Acyclovir; Administration, Topical; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chronic | 2006 |
Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cytarabine; Female; Foscarnet; Guinea | 1984 |
A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice.
Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Foscarnet; Ganglia, Spinal; Herpes | 1981 |
Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs.
Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Foscarnet; Ganglia, Spinal; Guinea | 1983 |
Suppression of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistant herpes simplex virus type 2 in mice.
Topics: Acyclovir; Animals; Arabinonucleosides; Brain; Chlorocebus aethiops; Drug Resistance, Microbial; Fos | 1995 |
Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient.
Topics: Acquired Immunodeficiency Syndrome; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fo | 1994 |
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1994 |
A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.
Topics: Acyclovir; Animals; Drug Resistance, Microbial; Evaluation Studies as Topic; Foscarnet; Herpes Genit | 1994 |
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Drug Therapy, C | 1994 |
[Acyclovir-resistant Herpes simplex viruses in HIV-infected patients].
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Female; Foscarn | 1993 |
Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency.
Topics: Acyclovir; Adult; Biopsy; Common Variable Immunodeficiency; Drug Resistance, Microbial; Female; Feta | 1997 |
Therapy for genital herpes in immunocompromised patients: a national survey. The Herpes Simplex Advisory Panel.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, | 1997 |
Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis.
Topics: Acyclovir; Administration, Topical; Antiviral Agents; Drug Resistance, Microbial; Female; Foscarnet; | 1998 |
Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance; Female; Fos | 1999 |
Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations.
Topics: Acyclovir; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Drug Resistance, | 2000 |
Herpes study and resources.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Biopolymers; Catechin; Clinical Trials as Topic; | 1997 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofov | 2001 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |
[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Dose-Response Relationship, | 1991 |
[Triapten ointment in the treatment of herpes genitalis in the female].
Topics: Antiviral Agents; Female; Foscarnet; Herpes Genitalis; Humans; Ointments; Phosphonoacetic Acid; Uter | 1990 |
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Acyclovir-resistant herpes in AIDS treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1988 |